1. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Issue 7 (July 2018) Authors: Rosenfeld, Margaret; Wainwright, Claire E.; Higgins, Mark; Wang, Linda T.; McKee, Charlotte; Campbell, Daniel; Tian, Simon; Schneider, Jennifer; Cunningham, Steve; Davies, Jane C.; Harris, William; Mogayzel, Peter; McCoy, Karen; Milla, Carlos; Rubenstein, Ronald; Walker, Seth; Black, Philip; Mont... Journal: Lancet Issue: Volume 6:Issue 7(2018) Page Start: 545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Issue 4 (April 2019) Authors: McNamara, John J; McColley, Susanna A; Marigowda, Gautham; Liu, Fang; Tian, Simon; Owen, Caroline A; Stiles, David; Li, Chonghua; Waltz, David; Wang, Linda T; Sawicki, Gregory S Journal: Lancet Issue: Volume 7:Issue 4(2019) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Similarity of chest X-ray and thermal imaging of focal pneumonia: a randomised proof of concept study at a large urban teaching hospital. Issue 1 (5th January 2018) Authors: Wang, Linda T; Cleveland, Robert H; Binder, William; Zwerdling, Robert G; Stamoulis, Caterina; Ptak, Thomas; Sherman, Mindy; Haver, Kenan; Sagar, Pallavi; Hibberd, Patricia Journal: BMJ open Issue: Volume 8:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗